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Abstract 
Background: Control efforts towards malaria due to Plasmodium falciparum significantly decreased the incidence of 
the disease in many endemic countries including Senegal. Surprisingly, in Kedougou (southeastern Senegal) P. falcipa-
rum malaria remains highly prevalent and the relative contribution of other Plasmodium species to the global malaria 
burden is very poorly documented, partly due to the low sensitivity of routine diagnostic tools. Molecular methods 
offer better estimate of circulating Plasmodium species in a given area. A molecular survey was carried out to docu‑
ment circulating malaria parasites in Kedougou region.
Methods: A total of 263 long‑term stored sera obtained from patients presenting with acute febrile illness in 
Kedougou between July 2009 and July 2013 were used for malaria parasite determination. Sera were withdrawn from 
a collection established as part of a surveillance programme of arboviruses infections in the region. Plasmodium spe‑
cies were characterized by a nested PCR‑based approach targeting the 18S small sub‑unit ribosomal RNA genes of 
Plasmodium spp.
Results: Of the 263 sera screened in this study, Plasmodium genomic DNA was amplifiable by nested PCR from 
62.35% (164/263) of samples. P. falciparum accounted for the majority of infections either as single in 85.97% (141/164) 
of Plasmodium‑positive samples or mixed with Plasmodium ovale (11.58%, 19/164) or Plasmodium vivax (1.21%, 2/164). 
All 19 (11.58%) P. ovale‑infected patients were mixed with P. falciparum, while no Plasmodium malariae was detected in 
this survey. Four patients (2.43%) were found to be infected by P. vivax, two of whom were mixed with P. falciparum. P. 
vivax infections originated from Bandafassi and Ninefesha villages and concerned patients aged 4, 9, 10, and 15 years 
old, respectively. DNA sequences alignment and phylogenetic analysis demonstrated that sequences from Kedougou 
corresponded to P. vivax, therefore confirming the presence of P. vivax infections in Senegal.
Conclusion: The results confirm the high prevalence of P. falciparum in Kedougou and provide the first molecular 
evidence of P. vivax infections in Senegal. These findings pave the ways for further investigations of P. vivax infections 
in Senegal and its contribution to the global burden of malaria disease before targeted strategies can be deployed.
© 2015 Niang et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria is a major infectious disease and remains 
the main global cause of death in many endemic 
areas, including Senegal. Success of malaria control 
interventions has led to a significant decrease of the dis-
ease burden. Between 2000 and 2013 malaria mortality 
rates decreased by 47% globally, and by 54% in sub-Saha-
ran Africa, the region most affected by the disease [1]. 
Among the five different species of the genus Plasmo-
dium (Plasmodium falciparum, Plasmodium vivax, Plas-
modium ovale, Plasmodium malariae, and Plasmodium 
knowlesi) known to infect humans [2], P. falciparum 
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remains the deadliest in Africa [1] and has been the 
major focus of malaria interventions.
With decreases in the P. falciparum burden resulting 
from successful malaria control interventions [1], atten-
tion must be focused on more than 400 million malaria 
cases due to other parasite species [3]. P. vivax, the most 
widespread of the Plasmodium species, is fast becoming 
a recognized cause of different grades of malaria pathol-
ogies along with an increasing trend in complicated 
malaria cases, thus threatening the prospect of malaria 
elimination in parts of Africa [4–8].
The presence of P. vivax malaria in sub-Saharan Africa 
has been largely neglected based on the demonstrated 
correlation between the lack of expression of the Duffy 
blood group in sub-Saharan African population and the 
absence of P. vivax infections [9, 10]. However recent 
reports of P. vivax infections in Duffy-negative individu-
als [7, 8, 11], have called for reconsideration of this widely 
accepted dogma as they strongly indicate that the Duffy 
status is no longer a barrier to P. vivax infection. More-
over, P. vivax appears to be more frequent in countries 
where either it was not present or it was not detected by 
the available techniques in the past, as is the case of some 
countries of West and Central [4, 6–8, 11, 12], becoming 
therefore a major source of concern.
To date, no P. vivax infection has been reported in 
Senegal despite evidence of its presence in many West 
African countries [4, 13–15]. A molecular survey of cir-
culating malaria parasites species was carried out on 
samples collected from acute febrile patients as part of 
a surveillance programme of arboviruses infections in 
Kedougou region, southeastern Senegal.
Methods
Study site
The study was conducted in the Kedougou region (Fig-
ure 1) located in southeast Senegal at the bordering area 
with Guinea, Mali and Gambia between isohyets 1,200 
and 1,300  mm. The climate is Sudano-Guinean with a 
single rainy season from May to November. The land-
scape consists of wooded grassland or woodland and 
dense gallery forest. The fauna is diverse with herbivo-
rous, insectivorous, rodents, and monkeys.
Malaria remains highly prevalent in Kedougou region 
and transmission is highly seasonal occurring during the 
rainy season (May–November). In 2014, the Senegalese 
National Malaria Control Programme reported 25.55% 
confirmed clinical malaria cases of which 2.73% turned 
into severe disease [16].
Population and study design
As part of a genetic diversity study of P. falciparum iso-
lates in concurrent malaria-arbovirus infections from 
patients presenting with acute febrile illness (AFI) in 
Kedougou, a molecular diagnostic was conducted to 
discriminate P. falciparum from other Plasmodium spe-
cies. This revealed a unique case of P. vivax infection 
in a patient from Ninefesha village. Therefore, addi-
tional samples from Ninefesha and nearby villages were 
retrieved from the sera collection and screened to survey 
P. vivax infections in Kedougou. A total of 263 sera from 
patients presenting with AFI between July 2009 and July 
2013 in the Kedougou region of Senegal were included in 
this study. Sera were withdrawn from a collection estab-
lished as part of a monitoring programme of arboviruses 
in Kedougou region. AFI was defined as ‘any patient older 
than 1 year with a fever (temperature >38°C) lasting for 
less than 2 weeks, exhibiting two or more of the follow-
ing symptoms: headache, myalgia, eye pain, arthralgia, 
cough, nausea/vomiting, diarrhoea, jaundice, bleeding 
and neurological signs’.
Ethical clearance
The study objectives, benefits and risks were explained 
in French language or local dialects to all participants 
before inclusion. Written informed consent was obtained 
from all adults participants and from the parents, or 
legal guardians of children. The study was examined and 
approved by the Senegalese National Health Research 
Committee.
Molecular detection of Plasmodium species
The detection of Plasmodium spp. genomic DNA 
(gDNA) in frozen serum samples has been reported 
earlier [17, 18]. Genomic DNA isolation of Plasmo-
dium parasites was performed using QIamp DNA Mini 
Kit (Qiagen, Hilden, Germany) according to manufac-
turer’s instructions. DNA extracted from blood samples 
of known microscopically confirmed P. falciparum, P. 
malariae and P. ovale-infected patients were used as pos-
itive controls. P. vivax gDNA was kindly donated by Dr 
Ambroise Ahouidi (Le Dantec Hospital, Dakar).
Qualitative detection of Plasmodium parasite DNA 
was based on nested PCR with primers targeting the 
Plasmodium spp. 18S small sub-unit ribosomal RNA 
(18S ssrRNA) gene as described previously [19]. The 
primary PCR amplification was performed with Plas-
modium genus-specific rPLU5 and rPLU6 primers pairs 
[20, 21] and 1.5 µl of template DNA in a total volume of 
25 µl using the GoTaq Green Master Mix protocol (Cata-
logue no M7113, Promega) according to manufacturer’s 
recommendations. The nested reaction was performed 
for the specific detection of Plasmodium species using 
previously described primers pairs rFAL1 and rFAL2 
for P. falciparum, rVIV1 and rVIV2 for P. vivax, rOVA1 
and rOVA2 for P. ovale and rMAL1 and rMAL2 for 
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P. malariae [20, 21]. The genus-specific primary PCR 
products (1 µl) were used as the template in the species-
nested PCR amplification under the same conditions. 
Nested PCR results were scored as categorical variable 
(presence vs. absence of amplification). PCR cycling reac-
tion and amplification conditions were as described by 
Snounou and Singh [19].
Purification of PCR products, DNA sequencing and analysis
In order to determine the sequences’ identity of the P. 
vivax amplified DNA, the specific bands were extracted 
from the gel and purified using the QIAquick Gel Extrac-
tion Kit as described by the manufacturer (Qiagen®). The 
purified PCR products were then sent to COGENICS for 
sequencing. For each DNA fragment, sequencing was 
performed from both the 3′ and 5′ directions (2× cover-
age). Consensus sequences were generated from the for-
ward and reverse sequences of each sample and used in 
a BLASTn algorithm against the Genbank database for 
similarity profile determination.
Sequence alignment and phylogenic trees were per-
formed using Mega 6.06 software. Plasmodium spp. small 
Figure 1 Map of Kedougou region showing villages where the majority of samples were obtained (blue star) and origin of the four Plasmodium 
vivax infections (red circle).
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sub-unit rRNA (SSU RNA) sequences were obtained 
from Plasmodb version 13.0 and Genbank. Plasmodium 
vivax: P. vivax Sal1_U030779.1, P. vivax_HF945443.1, P. 
vivax_HF945441.1; P. falciparum: JQ627152.1; P. ovale: 
JF894411.1; P. malariae: GU815531.1. Sequences were 
analysed by the Neighbour Joining method using 100 
bootstrap replicates.
Results
Characteristics of the study population
A total of 263 sera from patients presenting with AFI 
enrolled during arboviruses surveillance in Kedougou 
were screened in this study for the presence of malaria 
parasite species. Patients were aged one to 65 years old, 
the majority originated from the village of Bandafassi 
(Table 1). The mean age of the population varied between 
14  years (range 1–65  years) in Bandafassi and 23  years 
(range 4–60 years) in Kedougou (Table 1). The sex ratio 
was in favour of females in Bandafassi and in favour of 
males in others villages (Table 1).
Detection of malaria parasite species in patients by nested 
PCR
The four previously diagnosed clinical samples (P. fal-
ciparum, P. vivax, P. malariae, and P. ovale) and sterile 
distilled water were used as the positive and negative con-
trols, respectively to validate the nested PCR approach. 
The presence of amplified DNA products in a patient’s 
specimen corresponding to P. falciparum (205  bp), P. 
vivax (120 bp), P. malariae (144 bp) and P. ovale (375 bp) 
was confirmed (Figure 2).
Plasmodium genomic DNA was amplifiable by nested 
PCR from 62.35% (164/263) of the 263 sera screened 
in this study (Table  2). P. falciparum accounted for the 
majority of infections and was present either as single 
infections in 85.97% (141/164) of positive samples or 
mixed with P. ovale (11.58%, 19/164) or P. vivax (1.21%, 
2/164). Nineteen patients (11.58%) were infected with 
P. ovale, all of which were mixed with P. falciparum 
(Table  2). P. malariae was not detected in the current 
survey despite report of its presence in Kedougou (Ndi-
aye et  al. unpublished data). Four patients (2.43%) were 
found to be infected by P. vivax, two of which were 
mixed infections with P. falciparum (Table  2). Three of 
the four cases of P. vivax infections originated from the 
village of Bandafassi and concerned two females aged 4 
and 10 years old and one male aged 15 years. The fourth 
P. vivax case originated from a 9  years old female from 
Ninefesha village (Table 2).
Sequences analysis confirmation of Plasmodium vivax 
infections
To substantiate the PCR assays results on the four inci-
dences of P. vivax, DNA sequencing was performed for 
the four samples for gene specific to P. vivax. BLASTn 
analyses of the DNA sequences generated from the 
positive P. vivax samples confirmed that the P. vivax 
sequences from Kedougou (PVX_KDG1, PVX_KDG2, 
PVX_KDG3 and PVX_KDG4) matched the Genbank 
P. vivax isolate SV6 18S ribosomal RNA gene partial 
sequence (ID: JQ627158.1), P. vivax Sal1 blood stage 
small sub-unit rRNA gene (ID: PVU03079) and P. vivax 
isolate SV5 18S ribosomal RNA gene partial sequence 
(ID: JQ627157.1) by 98, 100, 100, and 97%, respectively 
(Figure 3).
Table 1 Characteristics of the study population
Kedougou Bandafassi Ninefesha Other Total
Number 57 149 34 23 263
Percentage (%) 21.67 56.65 12.93 8.75 100
Age
 Mean 23 14 16 21
 Range [4–60] [1–65] [1–62] [1–50]
Sex
 Male 31 73 19 13 136
 Female 26 76 15 10 127
 M/F 1.19 0.96 1.26 1.3
Figure 2 Gel picture showing positive amplification of Plasmodium 
vivax (120 bp), Plasmodium malariae (144 bp), Plasmodium falciparum 
(205 bp) and Plasmodium ovale (375 bp) 18S RNA gene. 100 bp DNA 
Ladder was used to determine molecular size.
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In addition, multiple sequences alignment of the four 
DNA sequences from P. vivax-infected samples and ref-
erence 18S rRNA gene sequence of P. vivax Sal1 strain 
indicated perfect homology with limited polymorphism 
between the Kedougou P. vivax DNA sequences and the 
reference P. vivax sequence, therefore demonstrating 
that sequences from Kedougou corresponded to P. vivax 
(Figure 4).
Consistent with the existence of different small sub-
unit RNA genes in P. vivax [22], phylogenetic analysis 
showed that sequences from Kedougou cluster with SSU 
RNA of P. vivax genes of different isolates and strains 
while branching-out from sequences of other Plasmo-
dium spp. (Figure 4). PVX_KDG1 and PVX_KDG4 were 
closely related to PVX_JQ627158.1 and PVX_JQ627157.1, 
respectively, while PVX_KDG2 and PVX_KDG3 clus-
tered with PVX-Sal1 reference strain (Figure  5). These 
observations are in accordance with the sequences analy-
sis data (Figure 3). Taken together, these results confirmed 
the presence of P. vivax infections in Senegal.
Discussion
The detection of P. falciparum and P. vivax DNA from 
serum samples of microscopically confirmed, malaria-
infected patients [17, 18] has demonstrated the feasibil-
ity for retrospective diagnosis of malaria infection in 
specimen banks of cohort studies, such as in determining 
malaria co-infection in HIV-seropositive populations or 
arboviruses-infected patients.
In the present study, nested PCR diagnostic assays 
targeting the 18S rRNA gene of Plasmodium species 
has been used to detect malaria parasite DNA in stored 
sera. The study revealed the predominance of P. falcipa-
rum either as single or mixed infections with P. vivax or 
P. ovale in Kedougou. The fact that all P. ovale infections 
detected in this study were mixed with P. falciparum sug-
gests that P. ovale infections might be underestimated 
by microscopy diagnostic. The high prevalence of P. fal-
ciparum in Kedougou and other regions in Senegal [16] 
largely justifies the targeted orientation of malaria con-
trol strategies against this species. It was surprising that 
P. malariae failed to be detected since studies in different 
areas of Senegal [23–25], including Kedougou (Ndiaye 
et  al. unpublished data), have documented the presence 
of P. malariae. The positive amplification obtained with 
Table 2 Details of single and mixed Plasmodium species infections in Kedougou
Site (sample size) Plasmodium species
P. falciparum P. vivax P. malariae P. ovale P. falciparum + P. vivax P. falciparum + P. ovale
Kedougou (57) 42 0 0 0 0 5
Bandafassi (149) 77 1 0 0 2 9
Ninefesha (34) 4 1 0 0 0 3
Others (23) 18 0 0 0 0 2
Total 141 2 0 0 2 19
Figure 3 BLASTn output of the sequences generated from the four 
Plasmodium vivax‑infected patients. Each of the sequences was que‑
ried against the Plasmodium GenBank data and number of hits with 
percentages identities displayed.
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parasite DNA from a microscopy-confirmed P. malariae-
infected patient in the nested PCR approach rules out a 
technical issue and undoubtedly confirms the absence of 
P. malariae in the screened samples. A possible explana-
tion of the absence of P. malariae in the surveyed samples 
might be a low parasitaemia below the detection limit of 
the nested PCR approach. Another explanation might be 
related to the low prevalence of P. malariae in the region. 
Both P. ovale and P. malariae have long been reported to 
be widely distributed in tropical Africa and other major 
malaria-endemic areas of the world [24, 26–28] and are 
often associated with P. falciparum infections [24, 27] as 
reported in this study for P. ovale.
The present study reports the first substantiated molec-
ular evidence of P. vivax infections in patients from 
Kedougou. There have been other reports of P. vivax else-
where on the African continent where P. vivax was ini-
tially thought to be absent [6, 7, 11, 13, 14, 29] due to the 
high prevalence of Duffy-negative individuals considered 
resistant to P. vivax infection [10, 30]. However, reports 
of documented P. vivax presence in West and Central 
African countries such as Congo [29], Cameroun [14, 15] 
and Mali [13] highly suggest that this parasite is evolving 
and adapting, becoming therefore a major public health 
concern. Infections caused by P. vivax, initially thought 
as ‘benign’ are now gaining higher importance, because 
of the very wide distribution of P. vivax parasite both 
in tropical and sub-tropical areas [31, 32] and the high 
number of reported clinical cases [31, 33, 34] along with 
documented cases of severe P. vivax disease and even 
deaths [35–37]. An important limitation of this study is 
the inability to link the confirmed P. vivax infections with 
the Duffy phenotypes of the individuals affected, thus the 
findings reported in the present study deserve to be sub-
stantiated by the determination of the Duffy status of the 
P. vivax-infected patients in order to gain insights into 
the mechanism underlying P. vivax infections in Kedou-
gou patients. The inability to link the reported P. vivax 
infections with the disease clinical outcome constitutes 
an additional limitation of the study. The presence of 
Duffy-positive ethnic groups that may be present in Sen-
egal, particularly in the Kedougou region, a gold-mining 
area attracting an important flux of migrants from neigh-
bouring countries, may account for P. vivax presence in 
the area. The recent adaptation of P. knowlesi, originally a 
simian malaria species, to human [2] suggests that a simi-
lar adaptation of the P. vivax parasite could be occurring, 
accounting for its increasing prevalence on the African 
continent.
In recent years, global efforts against malaria have 
shifted from control to specific strategies aimed at glob-
ally eliminating malaria in given areas, implying a need 
Figure 4 DNA sequence alignment of the four Senegalese Plasmodium vivax isolates with the reference DNA sequence of P. vivax SAL‑1 strain.
Figure 5 Bootstrapped phylogenetic rooted tree constructed 
by the Neighbour Joining method for the SSU rRNA sequences 
of Plasmodium vivax isolates from Kedougou. Horizontal branch 
lengths between nodes correspond to the number of shared derived 
changes. Plasmodium spp. small sub‑unit rRNA (SSU RNA) sequences 
were retrieved from Plasmodb.
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for accurate identification of both P. falciparum and 
non P. falciparum spp. that might sustain malaria trans-
mission. In Senegal, the National Malaria Control Pro-
gramme is already struggling to control malaria due to P. 
falciparum; the additional burden of P. vivax infections 
can therefore be daunting.
Conclusion
The present study provides the first molecular evidence of 
P. vivax infections in Kedougou (southeastern Senegal). 
Further investigations with a larger sampling in Kedou-
gou and other Senegalese settings are needed to docu-
ment the presence and prevalence of P. vivax infections 
in Senegal before orientated strategies can be deployed. 
The results presented here indicate that there may be a 
need for the National Malaria Control Programme to 
anticipate reviewing the management of malaria, includ-
ing P. vivax.
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